


## FTI-2153

Cat. No.:	HY-123242		
CAS No.:	344900-92-1		
Molecular Formula:	C <sub>25</sub> H <sub>30</sub> N <sub>4</sub> O <sub>3</sub> S		
Molecular Weight:	466.6		
Target:	Farnesyl Transferase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (214.32 mM; Need ultrasonic)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.1432 mL	10.7158 mL	21.4316 mL
	5 mM		0.4286 mL	2.1432 mL	4.2863 mL
	10 mM		0.2143 mL	1.0716 mL	2.1432 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

FTI-2153 is a potent and highly selective inhibitor of farnesyltransferase (FTase), with an IC<sub>50</sub> of 1.4 nM. FTI-2153 is >3000-fold more potent at blocking H-Ras (IC<sub>50</sub>, 10 nM) than Rap1A processing. Anti-cancer activity<sup>[1]</sup>.

### REFERENCES

---

[1]. Sun J, et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. *Cancer Res.* 1999 Oct 1;59(19):4919-26.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA